Overview
- The randomized POLY-HF trial tested a single pill containing metoprolol succinate, spironolactone, and empagliflozin against enhanced usual care over six months.
- Left ventricular ejection fraction improved by an additional 3% in the polypill group versus controls, with cardiac MRI used for measurement at baseline and follow-up.
- Heart-failure hospitalizations and emergency visits were about 60% lower with the polypill, and patients reported roughly 9-point higher KCCQ quality-of-life scores.
- Objective adherence was higher with the combination pill, with detectable drug levels in 79% of polypill patients compared with 54% receiving separate medications.
- All participants also received sacubitril-valsartan separately, the cohort was racially and socioeconomically diverse, and investigators plan further implementation studies.